IRVINE, Calif.--(BUSINESS WIRE)--April 5, 2006--Cobalis Corp. (OTC BB: CLSC - News), a pharmaceutical development company specializing in anti-allergy medications, announced today that the Company has reached and executed a settlement agreement with Gryphon Master Fund, L.P. of Dallas, TX. Both Gryphon and Cobalis have further agreed to dismiss any and all current and future claims, legal proceedings and litigation.
